{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:08:33Z","timestamp":1787162913584,"version":"build-2736575974"},"reference-count":11,"publisher":"Impact Journals, LLC","issue":"57","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,10,15]]},"DOI":"10.18632\/oncotarget.27203","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T13:00:38Z","timestamp":1571144438000},"page":"6038-6042","source":"Crossref","is-referenced-by-count":40,"title":["Newly diagnosed papillary craniopharyngioma with\n                    <i>BRAF V600E<\/i>\n                    mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report"],"prefix":"10.18632","volume":"10","author":[{"given":"Mayank","family":"Rao","sequence":"first","affiliation":[{"name":"The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Shepard","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigmund","family":"Hsu","sequence":"additional","affiliation":[{"name":"The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1530\/EJE-15-0957","article-title":"ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma","volume":"174","author":"Santagata","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2016.9.FOCUS16325","article-title":"Diagnosis and management of craniopharyngiomas in the era of genomics and target therapy","volume":"41","author":"Brastianos","year":"2016","journal-title":"Neurosurg Focus"},{"key":"3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Calicchio","year":"2014","journal-title":"Nat Genet"},{"key":"4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/DDDT.S38998","article-title":"Dabrafenib and its potential for the treatment of metastatic melanoma","volume":"6","author":"Murali","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Mauch","year":"2012","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Schachter","year":"2017","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Brastianos, Shankar, Gill, Taylor-Weiner, Nayyar, Panka, Sullivan, Frederick, Abedalthagafi, Jones, Dunn, Nahed, Romero, et al. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2015; 108:djv310. https:\/\/doi.org\/10.1093\/jnci\/djv310.","DOI":"10.1093\/jnci\/djv310"},{"key":"8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Odia","year":"2017","journal-title":"CNS Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Gudjonsson","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"key":"10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Beaney","year":"2016","journal-title":"Pituitary"},{"key":"11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3171\/2017.11.jns172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with Dabrafenib: case report","volume":"130","author":"Uhm","year":"2018","journal-title":"J Neurosurg"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T11:08:13Z","timestamp":1591441693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":11,"journal-issue":{"issue":"57","published-print":{"date-parts":[[2019,10,15]]}},"alternative-id":["27203","31666933"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27203","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}